RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
107M of 99M shares
Institutional holders
310
59 new, 44 sold out
Net institutional buying
9M
In Q2 2026
Insider trades, 12 months
0 buys · 27 sales
Net sold $3.70M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,141,384 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Roderick Wong | 7,796,895 | 7.90% | 13G (passive) | Jun 30, 2026 |
| Vanguard Portfolio Management | 6,853,427 | 6.95% | 13G (passive) amendment | Jun 30, 2026 |
| AQR Capital Management, LLC | 6,560,809 | 6.66% | 13G (passive) | Jun 30, 2026 |
| State Street Corporation | 6,158,766 | 6.30% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 5,058,419 | 5.13% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RARE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,654,276 | 10.81% | $355.75M | +3,354,678 | 0.01% |
| Rtw Investments, LP | 7,796,895 | 7.91% | $260.34M | +4,148,100 | 2.22% |
| Vanguard Portfolio Management LLC | 6,790,135 | 6.89% | $226.72M | +1,404,143 | 0.01% |
| Aqr Capital Management LLC | 6,560,809 | 6.65% | $214.14M | +1,982,785 | 0.07% |
| State Street Corp | 6,158,766 | 6.25% | $205.64M | +1,137,325 | 0.01% |
| Vanguard Capital Management LLC | 4,296,491 | 4.36% | $143.46M | +106,660 | 0.00% |
| Two Sigma Investments, LP | 3,621,200 | 3.67% | $120.91M | +1,415,380 | 0.09% |
| Sands Capital Management, LLC | 3,158,368 | 3.20% | $105.46M | −56,165 | 0.39% |
| Jacobs Levy Equity Management, Inc | 2,939,719 | 2.98% | $98.16M | +1,508,648 | 0.35% |
| Frontier Capital Management Co LLC | 2,847,936 | 2.89% | $95.09M | +656,754 | 0.89% |
| Geode Capital Management, LLC | 2,578,828 | 2.62% | $86.12M | +729,437 | 0.00% |
| Bellevue Group AG | 1,982,775 | 2.01% | $66.20M | −397,225 | 1.39% |
| D. E. Shaw & Co., Inc. | 1,730,193 | 1.75% | $57.77M | +469,175 | 0.03% |
| Sofinnova Investments, Inc. | 1,717,505 | 1.74% | $57.35M | −1,428,383 | 2.96% |
| Adage Capital Partners Gp, L.L.C. | 1,580,000 | 1.60% | $52.76M | +1,100,000 | 0.07% |
| GW&K Investment Management, LLC | 1,481,178 | 1.50% | $49.46K | −134,248 | 0.39% |
| Mpm Bioimpact LLC | 1,418,215 | 1.44% | $47.35M | New | 2.89% |
| Price T Rowe Associates Inc /Md/ | 1,356,501 | 1.38% | $45.30K | +552,392 | 0.00% |
| Morgan Stanley | 1,324,805 | 1.34% | $44.24M | −175,723 | 0.00% |
| Wellington Management Group Llp | 1,250,464 | 1.27% | $41.75M | −1,390,348 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 310 | 107M | 100.0% | 59 / 116 | 98 / 44 | 28M | 19M |
| Q1 2026 | 298 | 98M | 99.6% | 63 / 125 | 84 / 49 | 42M | 27M |
| Q4 2025 | 288 | 94M | 95.3% | 57 / 111 | 91 / 65 | 19M | 23M |
| Q3 2025 | 303 | 100M | 100.0% | 53 / 131 | 91 / 57 | 27M | 21M |
| Q2 2025 | 310 | 94M | 95.5% | 54 / 117 | 108 / 43 | 14M | 10M |
| Q1 2025 | 300 | 90M | 91.2% | 34 / 126 | 105 / 44 | 10M | 7M |
| Q4 2024 | 313 | 88M | 88.8% | 55 / 111 | 109 / 42 | 10M | 10M |
| Q3 2024 | 302 | 87M | 88.4% | 59 / 110 | 93 / 29 | 15M | 11M |
| Q2 2024 | 275 | 89M | 90.1% | 47 / 117 | 80 / 40 | 17M | 9M |
| Q1 2024 | 270 | 81M | 82.3% | 53 / 100 | 76 / 20 | 7M | 8M |
| Q4 2023 | 237 | 82M | 82.8% | 44 / 95 | 74 / 23 | 17M | 6M |
| Q3 2023 | 220 | 71M | 72.3% | 11 / 105 | 73 / 33 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RARE | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,666,868 | 3.72% | $122.44M | 1.14% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,986,621 | 3.03% | $99.72M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,501,996 | 2.54% | $83.54M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,144,802 | 2.18% | $71.61M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,238,640 | 1.26% | $41.36M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,127,711 | 1.14% | $37.65M | 0.04% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 1,072,214 | 1.09% | $35.80M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,055,493 | 1.07% | $26.29M | 0.08% | Jul 31, 2026 |
| AQR Long-Short Equity Fund | 914,718 | 0.93% | $30.54M | 0.39% | Jun 30, 2026 |
| Vanguard Explorer Fund | 821,986 | 0.83% | $20.48M | 0.09% | Jul 31, 2026 |
| iShares Biotechnology ETF | 635,346 | 0.64% | $21.21M | 0.23% | Jun 30, 2026 |
| Touchstone Funds Group Trust-Touchstone Sands Capital Select Growth Fund | 611,950 | 0.62% | $20.43M | 0.92% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 527,813 | 0.54% | $12.64M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 500,243 | 0.51% | $11.98M | 0.03% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 496,620 | 0.50% | $16.58M | 0.11% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Emil D. Kakkis | President & CEO, Director | 2,694,724 | 2.73% | Apr 20, 2026 |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | 67,863 | 0.07% | Sep 15, 2026 |
| Howard Horn | Chief Financial Officer | 96,295 | 0.10% | Aug 4, 2026 |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | 92,562 | 0.09% | Aug 4, 2026 |
| Eric Crombez | EVP and Chief Medical Officer | 111,189 | 0.11% | May 6, 2026 |
| Erik Harris | EVP & Chief Commercial Officer | 118,410 | 0.12% | Apr 20, 2026 |
| John Richard Pinion | See Remarks | 133,142 | 0.14% | Apr 20, 2026 |
| Dennis Karl Huang | See Remarks | 147,845 | 0.15% | Apr 20, 2026 |
| Thomas Richard Kassberg | CBO & EVP | 265,238 | 0.27% | Mar 4, 2025 |
| Corazon (Corsee) D. Sanders | Director | 21,095 | 0.02% | Jun 15, 2026 |
| Daniel G. Welch | Director | 40,441 | 0.04% | May 18, 2026 |
| Michael Narachi | Director | 40,441 | 0.04% | May 18, 2026 |
| Deborah Dunsire | Director | 38,566 | 0.04% | May 18, 2026 |
| Amrit Ray | Director | 31,116 | 0.03% | May 18, 2026 |
| Shehnaaz Suliman | Director | 27,951 | 0.03% | May 18, 2026 |
| Matthew K. Fust | Director | 33,696 | 0.03% | May 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −1,283 | $13.57 | $17.41K | 67,863 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 3, 2026 | Sale | −161 | $13.99 | $2.25K | 69,146 |
| Howard Horn Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −4,696 | $24.92 | $117.02K | 96,295 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −1,900 | $24.92 | $47.35K | 92,562 |
| Howard Horn Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −4,698 | $33.13 | $155.64K | 100,991 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −1,899 | $24.62 | $46.75K | 94,462 |
| Corazon (Corsee) D. Sanders Director | Jun 15, 2026 | Sale | −2,000 | $25.05 | $50.10K | 21,095 |
| Howard Horn Chief Financial Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −4,653 | $23.77 | $110.60K | 105,689 |
| Shehnaaz Suliman Director | May 18, 2026 | Sale(10b5-1 plan) | −5,740 | $25.12 | $144.19K | 27,951 |
| Shehnaaz Suliman Director | May 14, 2026 | Award | +7,751 | – | – | 33,691 |
| Michael Narachi Director | May 14, 2026 | Award | +7,751 | – | – | 40,441 |
| Daniel G. Welch Director | May 14, 2026 | Award | +7,751 | – | – | 40,441 |
| Deborah Dunsire Director | May 14, 2026 | Award | +7,751 | – | – | 38,566 |
| Corazon (Corsee) D. Sanders Director | May 14, 2026 | Award | +7,751 | – | – | 23,095 |
| Amrit Ray Director | May 14, 2026 | Award | +7,751 | – | – | 31,116 |
| Matthew K. Fust Director | May 14, 2026 | Award | +7,751 | – | – | 33,696 |
| Eric Crombez EVP and Chief Medical Officer | May 5, 2026 | Sale | −344 | $24.96 | $8.59K | 111,189 |
| Howard Horn Chief Financial Officer | May 1, 2026 | Sale(10b5-1 plan) | −4,683 | $24.90 | $116.61K | 110,342 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Apr 22, 2026 | Award | +20,241 | – | – | 68,911 |
| John Richard Pinion See Remarks | Apr 16, 2026 | Award | +23,116 | – | – | 133,142 |
| Dennis Karl Huang See Remarks | Apr 16, 2026 | Award | +23,116 | – | – | 147,845 |
| Eric Crombez EVP and Chief Medical Officer | Apr 16, 2026 | Award | +34,674 | – | – | 110,975 |
| Howard Horn Chief Financial Officer | Apr 16, 2026 | Award | +34,674 | – | – | 115,025 |
| Emil D. Kakkis President & CEO, Director | Apr 16, 2026 | Award | +76,745 | – | – | 735,739 |
| Erik Harris EVP & Chief Commercial Officer | Apr 16, 2026 | Award | +28,895 | – | – | 118,410 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Apr 16, 2026 | Award | +28,895 | – | – | 95,715 |
| Howard Horn Chief Financial Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −4,683 | $20.97 | $98.20K | 80,351 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 10, 2026 | Sale | −3,508 | $22.67 | $79.53K | 66,820 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 6, 2026 | Sale | −6,018 | $21.40 | $128.79K | 70,328 |
| Howard Horn Chief Financial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −1,635 | $22.40 | $36.62K | 85,034 |
| Howard Horn Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −3,119 | $22.54 | $70.30K | 86,669 |
| Howard Horn Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −5,290 | $22.80 | $120.61K | 89,788 |
| Emil D. Kakkis President & CEO, Director | Mar 2, 2026 | Sale | −54,404 | $22.80 | $1.24M | 658,994 |
| Dennis Karl Huang See Remarks | Mar 2, 2026 | Tax withholding | −999 | $23.39 | $23.37K | 124,729 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Mar 2, 2026 | Tax withholding | −148 | $23.39 | $3.46K | 50,302 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Mar 2, 2026 | Sale | −1,632 | $22.80 | $37.21K | 48,670 |
| Erik Harris EVP & Chief Commercial Officer | Mar 2, 2026 | Sale | −10,539 | $22.80 | $240.29K | 89,515 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 2, 2026 | Sale | −8,135 | $22.80 | $185.48K | 76,346 |
| Eric Crombez EVP and Chief Medical Officer | Mar 2, 2026 | Sale | −7,029 | $22.80 | $160.26K | 76,301 |
| John Richard Pinion See Remarks | Mar 2, 2026 | Sale | −10,029 | $22.80 | $228.66K | 110,026 |
| Howard Horn Chief Financial Officer | Mar 1, 2026 | Award | +6,143 | – | – | 95,078 |
| Emil D. Kakkis President & CEO, Director | Mar 1, 2026 | Award | +71,177 | – | – | 712,908 |
| Dennis Karl Huang See Remarks | Mar 1, 2026 | Award | +11,137 | – | – | 125,728 |
| Erik Harris EVP & Chief Commercial Officer | Mar 1, 2026 | Award | +11,643 | – | – | 99,498 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Mar 1, 2026 | Award | +11,137 | – | – | 84,408 |
| Eric Crombez EVP and Chief Medical Officer | Mar 1, 2026 | Award | +11,643 | – | – | 83,173 |
| John Richard Pinion See Remarks | Mar 1, 2026 | Award | +11,137 | – | – | 119,565 |
| Howard Horn Chief Financial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −3,061 | $23.56 | $72.12K | 88,935 |
| Howard Horn Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −3,150 | $22.84 | $71.95K | 91,996 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Dec 29, 2025 | Sale | −85 | $34.38 | $2.92K | 50,450 |
| Howard Horn Chief Financial Officer | Dec 10, 2025 | Sale(10b5-1 plan) | −3,081 | $36.38 | $112.09K | 95,146 |
| Howard Horn Chief Financial Officer | Oct 13, 2025 | Sale | −7,942 | $31.51 | $250.25K | 98,227 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 18, 2025 | Sale | −64 | $29.17 | $1.87K | 50,242 |
| Karah Herdman Parschauer EVP and Chief Legal Officer | Sep 12, 2025 | Sale | −2,450 | $31.17 | $76.37K | 73,271 |
| Theodore Alan Huizenga SVP, Chief Accounting Officer | Sep 5, 2025 | Sale | −84 | $31.39 | $2.64K | 50,306 |
| Corazon (Corsee) D. Sanders Director | Jun 20, 2025 | Sale(10b5-1 plan) | −2,405 | $37.39 | $89.92K | 15,344 |
| Matthew K. Fust Director | May 15, 2025 | Award | +5,740 | – | – | 25,945 |
| Shehnaaz Suliman Director | May 15, 2025 | Award | +5,740 | – | – | 25,940 |
| Corazon (Corsee) D. Sanders Director | May 15, 2025 | Award | +5,740 | – | – | 17,749 |
| Michael Narachi Director | May 15, 2025 | Award | +5,740 | – | – | 32,690 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Huizenga Theodore Officer | Sep 15, 2026 | 1,283 | $17.46K | Sep 15, 2026 | Performance Stock Units |
| Horn Howard Officer | Aug 3, 2026 | 4,696 | $117.02K | Aug 3, 2026 | Restricted Stock and Performance Shares |
| Horn Howard Officer | Jul 1, 2026 | 4,698 | $155.64K | Jul 1, 2026 | Restricted Stock |
| Parschauer Karah Officer | Jun 15, 2026 | 3,799 | $92.51K | Jun 15, 2026 | Performance Stock Units |
| D. Sanders Corazon Director | Jun 15, 2026 | 2,000 | $50.10K | Jun 15, 2026 | Restricted Stock |
| Horn Howard Officer | Jun 1, 2026 | 4,653 | $110.60K | Jun 1, 2026 | Performance and Restricted Stock |
| Suliman Shehnaaz Director | May 18, 2026 | 5,740 | $144.19K | May 18, 2026 | Restricted Stock |
| Horn Howard Officer | May 1, 2026 | 4,683 | $116.61K | May 1, 2026 | Restricted Stock |
| Horn Howard Officer | Apr 1, 2026 | 4,683 | $98.20K | Apr 1, 2026 | Restricted Stock |
| Parschauer Karah Officer | Mar 10, 2026 | 3,508 | $79.53K | Mar 10, 2026 | Restricted Stock |
| Parschauer Karah Officer | Mar 6, 2026 | 6,018 | $128.77K | Mar 6, 2026 | Performance Shares |
| Horn Howard Officer | Mar 3, 2026 | 1,635 | $36.62K | Mar 3, 2026 | Performance Shares |
| Horn Howard Officer | Mar 2, 2026 | 3,119 | $70.30K | Mar 2, 2026 | Restricted Stock |
| Horn Howard Officer | Feb 2, 2026 | 3,061 | $72.12K | Feb 2, 2026 | Restricted Stock |
| Horn Howard Officer | Jan 2, 2026 | 3,150 | $71.95K | Jan 2, 2026 | Restricted Stock |